Moreover, overexpression of NSD2 has been identified as an adverse prognostic marker for MM, and recent studies have revealed that NSD2 enhances drug resistance of MM through H4K20me3-mediated recruitment of 53BP1 and enhanced repair of DNA damage14. Here, NSD2 is linked to Miyoshi myopathy.